121 related articles for article (PubMed ID: 34979565)
1. Reporting Subclonal Immunohistochemical Staining of Mismatch Repair Proteins in Endometrial Carcinoma in the Times of Ever-Changing Guidelines.
Scheiderer A; Riedinger C; Kimball K; Kilgore L; Orucevic A
Arch Pathol Lab Med; 2022 Sep; 146(9):1114-1121. PubMed ID: 34979565
[TBL] [Abstract][Full Text] [Related]
2. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
3. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
4. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
Riedinger CJ; Esnakula A; Haight PJ; Suarez AA; Chen W; Gillespie J; Villacres A; Chassen A; Cohn DE; Goodfellow PJ; Cosgrove CM
Cancer; 2024 Feb; 130(3):385-399. PubMed ID: 37751191
[TBL] [Abstract][Full Text] [Related]
5. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
7. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Chapel DB; Yamada SD; Cowan M; Lastra RR
Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
[TBL] [Abstract][Full Text] [Related]
8. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
9. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
10. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
[TBL] [Abstract][Full Text] [Related]
11. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM
Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226
[TBL] [Abstract][Full Text] [Related]
12. Unusual Mismatch Repair Immunohistochemical Patterns in Endometrial Carcinoma.
Watkins JC; Nucci MR; Ritterhouse LL; Howitt BE; Sholl LM
Am J Surg Pathol; 2016 Jul; 40(7):909-16. PubMed ID: 27186853
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
14. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
[TBL] [Abstract][Full Text] [Related]
15. Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins: A Clinicopathologic and Genomic Study.
Mendoza RP; Wang P; Schulte JJ; Tjota MY; Jani I; Martinez AC; Haridas R; Wanjari P; Steinhardt G; Brown N; Betz BL; Chapel DB; Kertowidjojo E; Yamada SD; Bennett JA
Am J Surg Pathol; 2023 May; 47(5):589-598. PubMed ID: 36866757
[TBL] [Abstract][Full Text] [Related]
16. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report.
Chapel DB; Lengyel E; Ritterhouse LL; Lastra RR
Int J Gynecol Pathol; 2020 May; 39(3):233-237. PubMed ID: 30807370
[TBL] [Abstract][Full Text] [Related]
17. Lynch Syndrome in Thai Endometrial Cancer Patients.
Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
[TBL] [Abstract][Full Text] [Related]
18. EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer.
Mrkonjic M; Turashvili G
Am J Surg Pathol; 2022 Mar; 46(3):376-382. PubMed ID: 34772843
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
20. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
